The University of Southampton
University of Southampton Institutional Repository

Cost-effectiveness of interferon ? or peginterferon ?, with ribavirin for histologically mild chronic hepatitis C

Record type: Article

Background: For patients with mild chronic hepatitis C the cost-effectiveness of antiviral therapy is unknown.
Aims: To assess whether anti-viral therapy (either interferon ? or peginterferon ? combined with ribavirin) is cost-effective at a mild stage compared to waiting and only treating those cases whoprogress to moderate disease.
Patients: Cases with mild chronic hepatitis C.
Methods: A cost-effectiveness model estimates long-term costs and outcomes for patients with mild chronic hepatitis C. The model uses effectiveness and cost data from the UK mild hepatitis C RCT, combined with estimates of disease progression and cost from observational studies.
Results: Antiviral treatment at a mild rather than a moderate stage improved outcomes measured by Quality Adjusted Life Years (QALYs) gained. The mean cost per QALY gained from antiviral treatment with interferon ??2b and ribavirin, compared to no treatment at a mild stage, was £4,535 ($7,108) for patients with genotype non-1 and £25,188 ($39,480) for patients with genotype 1. Providing peginterferon ??2b and ribavirin at a mild rather than a moderate stage was also associated with a gain in QALYs; the costs per QALY gained were £7,821 ($12,259) for patients with genotype non-1 and £28,409 ($44,528) for patients with genotype 1.
Conclusions: For patients with chronic hepatitis C, it is generally more cost-effective to provide antiviral treatment at a mild rather than a moderate disease stage. For older patients (aged 65 or over) with genotype 1, antiviral treatment at a mild stage is not cost-effective.

Full text not available from this repository.

Citation

Grieve, Richard, Roberts, Jennifer, Wright, Mark, Sweeting, Michael, DeAngelis, Daniela, Rosenberg, William, Bassendine, Margaret, Main, Janice and Thomas, Howard (2006) Cost-effectiveness of interferon ? or peginterferon ?, with ribavirin for histologically mild chronic hepatitis C Gut, 55, (9), pp. 1332-1338. (doi:10.1136/gut.2005.064774).

More information

Published date: 2006
Keywords: cost-effectiveness model, cost analysis, antiviral therapy

Identifiers

Local EPrints ID: 27074
URI: http://eprints.soton.ac.uk/id/eprint/27074
ISSN: 0017-5749
PURE UUID: 5655188d-e032-4c3e-9754-7c0dfdeb78d5

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 17 Jul 2017 16:05

Export record

Altmetrics

Contributors

Author: Richard Grieve
Author: Jennifer Roberts
Author: Mark Wright
Author: Michael Sweeting
Author: Daniela DeAngelis
Author: William Rosenberg
Author: Margaret Bassendine
Author: Janice Main
Author: Howard Thomas

University divisions


Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×